Awake breast cancer surgery: strategy in the beginning of COVID-19 emergency.
Aged
Anesthesia
/ methods
Breast Neoplasms
/ pathology
COVID-19
/ prevention & control
Female
Humans
Italy
Length of Stay
Lymph Node Excision
Mastectomy
/ adverse effects
Mastectomy, Segmental
/ adverse effects
Middle Aged
Operative Time
Postoperative Complications
/ etiology
Retrospective Studies
Wakefulness
Awake surgery
Breast cancer
COVID-19
Conservative surgery
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
14
04
2020
accepted:
16
07
2020
pubmed:
1
8
2020
medline:
15
1
2021
entrez:
1
8
2020
Statut:
ppublish
Résumé
COVID-19 is a declared worldwide pandemic. In our country, due to shortage of hospitals and beds in intensive care unit, oncological and breast cancer (BC) resources are temporarily shifted to COVID-19 patients. In addition, risk of cross-infections should be considered in these frail patients. To accomplish more surgical procedures and to reduce the length of hospital stay (LOS), fast track awake BC surgery should be implemented. The aim of the study is to estimate the effects of surgical shift in our facility during the early COVID-19 outbreak. From 30th January 2020 to 30th of March 2020, 86 consecutive patients were retrospectively enrolled and divided into pre-COVID-19-BC and COVID-19-BC. Clinical parameters and anamnestic data were collected and analyzed. Surgical procedures, relative complications and type of anaesthesia were reported. The effect on surgical time (ST), operative room time (ORT) and length of stay (LOS) were described and examined. No statistical difference was found in complications rate, clinical data and surgical procedures (p > 0.05). Awake breast conservative surgery (BCS) was the most frequent procedure in COVID-19-BC (p = 0.006). A statistically significant decrease in ORT and LOS was reported in COVID-19-BC (p = 0.040 and p = 0.0015 respectively), while comparable time resulted for ST (p = 0.976). Mean ORT and LOS reduction were 20.79 min and 0.57 hospital bed days. In the "COVID-19 era", fast track awake breast surgery provides a reduction of ORT, LOS and potentially surgical treatment for a wider number of oncological patients.
Identifiants
pubmed: 32734327
doi: 10.1007/s12282-020-01137-5
pii: 10.1007/s12282-020-01137-5
pmc: PMC7391474
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
137-144Références
Updates Surg. 2020 Jun;72(2):537-546
pubmed: 32062785
Surgery. 2017 May;161(5):1430-1435
pubmed: 28043695
World J Surg. 2019 Mar;43(3):839-845
pubmed: 30456482
Zhonghua Zhong Liu Za Zhi. 2020 Apr 23;42(4):288-291
pubmed: 32100979
BMJ. 2018 Apr 25;361:k1415
pubmed: 29695476
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Feb 25;23(2):I-IV
pubmed: 32074786
N Engl J Med. 2020 May 14;382(20):1873-1875
pubmed: 32187459
Int J Mol Sci. 2017 Jul 07;18(7):
pubmed: 28686211
Zhonghua Zhong Liu Za Zhi. 2020 Mar 23;42(3):187-191
pubmed: 32108460
Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1341-1345
pubmed: 28387892
Zhonghua Zhong Liu Za Zhi. 2020 Mar 23;42(3):184-186
pubmed: 32112549
In Vivo. 2020 May-Jun;34(3):1125-1132
pubmed: 32354901
In Vivo. 2019 Nov-Dec;33(6):1879-1884
pubmed: 31662515
Ann Thorac Surg. 2010 Sep;90(3):973-8
pubmed: 20732526
JAMA Surg. 2017 Mar 1;152(3):292-298
pubmed: 28097305
Anticancer Res. 2020 Mar;40(3):1719-1729
pubmed: 32132080
Can J Anaesth. 2020 Jul;67(7):885-892
pubmed: 32212103
Dan Med J. 2018 Mar;65(3):
pubmed: 29510807
Anticancer Res. 2020 Feb;40(2):939-950
pubmed: 32014938
Yeungnam Univ J Med. 2019 Aug 26;36(3):201-207
pubmed: 31620634
Zhonghua Wai Ke Za Zhi. 2020 May 1;58(5):331-336
pubmed: 32096395
Anticancer Res. 2020 Jan;40(1):281-286
pubmed: 31892577
Clin Infect Dis. 2007 Apr 15;44(8):1017-25
pubmed: 17366443
World J Surg. 2017 Apr;41(4):899-913
pubmed: 27822725
Chest. 2006 Sep;130(3):730-40
pubmed: 16963670
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
Cancers (Basel). 2019 Feb 21;11(2):
pubmed: 30795637
Eur Rev Med Pharmacol Sci. 2016 Jul;20(14):2950-4
pubmed: 27460720
Eur J Surg Oncol. 2017 Feb;43(2):303-310
pubmed: 28069398
Int J Surg. 2014;12(4):334-9
pubmed: 24486930